|
The Journal of Lipid Research, Vol. 40, 486-494, March 1999
Copyright © 1999 by Lipid Research, Inc.
Multiple dysfunctions of two apolipoprotein A-I variants, apoA-I(R160L)Oslo and apoA-I(P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers
Ulrike Dauma,b,
Trond P. Lerenc,
Claus Langera,b,
Ali Chirazia,b,
Paul Cullena,b,
P. Haydn Pritchardd,
Gerd Assmanna,b, and
Arnold von Eckardsteina,b
a Institut für Arterioskleroseforschung an der Universität Münster, Domagkstrasse 3, D-48149 Münster, Germany
b Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Westfälische Wilhelms-Universität, Albert-Schweitzer-Strasse 33, D-48129 Münster, Germany
c Medinnova/MSD Cardiovascular Research Centre, Rikshospitalet, N-0027 Oslo, Norway
d Department of Pathology and Laboratory Medicine, St. Paul's Hospital, #180-1081 Burrard Street, Vancouver, British Columbia, Canada V6Z 1Y6
Correspondence to:
Arnold von Eckardstein
ApoA-I(R160L)Oslo and apoA-I(P165R) are naturally occurring apolipoprotein (apo) A-I variants that are associated with low HDL-cholesterol in heterozygous carriers. We characterized the capacity of these variants to bind lipid, to activate lecithin:cholesterol acyltransferase (LCAT), and to promote efflux of biosynthetic cholesterol from porcine aortic smooth muscle cells (SMCs) or exogenous cholesterol from lipid-loaded mouse peritoneal macrophages. During cholate dialysis, normal apoA-I and both variants associated completely with dipalmitoylphosphatidylcholine (DPPC) and formed rLpA-I of identical size. However, both apoA-I(P165R) and apoA-I(R160L)Oslo showed a reduced capacity to clear a turbid emulsion of dimyristoylphosphatidylcholine (DMPC). Compared to normal apoA-I, the LCAT-cofactor activity of apoA-I(P165R) and apoA-I(R160L)Oslo as defined by the ratio of Vmax to appKm was reduced significantly by 62% and 29%, respectively (here and throughout the text, the apparent Km is given as Michaelis-Menten kinetics do not take particle binding into account and therefore would result in errors with an interfacial enzyme such as LCAT; Vmax estimates are not affected by this error). ApoA-I/DPPC complexes induced biphasic cholesterol efflux from SMCs with a fast and a slow efflux component. Compared to rLpA-I reconstituted with wild type apoA-I, rLpA-I with apoA-I(P165R) or apoA-I(R160L)Oslo were significantly less effective in promoting cholesterol efflux from SMCs in incubations of 10 min duration but equally effective in incubations of 6 h duration. Lipid-free apoA-I did not induce efflux of biosynthetic cholesterol from SMCs but induced hydrolysis of cholesteryl esters and cholesterol efflux from acetyl-LDL-loaded mouse peritoneal macrophages. In the lipid-free form, both apoA-I variants promoted normal cholesterol efflux from murine peritoneal macrophages.
We conclude that amino acid residues arginine 160 and proline 165 of apoA-I contribute to the formation of a domain that is very important for initial lipid binding and contributes to LCAT-activation and promotion of initial cholesterol efflux but not to the stabilization of preformed rLpA-I.Daum, U., T. P. Leren, C. Langer, A. Chirazi, P. Cullen, P. H. Pritchard, G. Assmann, and A. von Eckardstein. Multiple dysfunctions of two apolipoprotein A-I variants, apoA-I(R160L)Oslo and apoA-I(P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers. J. Lipid Res. 1999. 40: 486494.
Supplementary key words:
familial hypoalphalipoproteinemia, apoA-I variants, cholesterol efflux, LCAT, reverse cholesterol transport

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. S. Kiss, N. Kavaslar, K.-i. Okuhira, M. W. Freeman, S. Walter, R. W. Milne, R. McPherson, and Y. L. Marcel
Genetic Etiology of Isolated Low HDL Syndrome: Incidence and Heterogeneity of Efflux Defects
Arterioscler. Thromb. Vasc. Biol.,
May 1, 2007;
27(5):
1139 - 1145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Haidar, R. S. Kiss, L. Sarov-Blat, R. Brunet, C. Harder, R. McPherson, and Y. L. Marcel
Cathepsin D, a Lysosomal Protease, Regulates ABCA1-mediated Lipid Efflux
J. Biol. Chem.,
December 29, 2006;
281(52):
39971 - 39981.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kontush and M. J. Chapman
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Pharmacol. Rev.,
September 1, 2006;
58(3):
342 - 374.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. K. Hovingh, A. Brownlie, R. J. Bisoendial, M. P. Dube, J. H.M. Levels, W. Petersen, R. P.F. Dullaart, E. S.G. Stroes, A. H. Zwinderman, E. de Groot, et al.
A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease
J. Am. Coll. Cardiol.,
October 6, 2004;
44(7):
1429 - 1435.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Sviridov, A. Hoang, W. Huang, and J. Sasaki
Structure-function studies of apoA-I variants: site-directed mutagenesis and natural mutations
J. Lipid Res.,
August 1, 2002;
43(8):
1283 - 1292.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-H. Cho, D. M. Durbin, and A. Jonas
Role of individual amino acids of apolipoprotein A-I in the activation of lecithin:cholesterol acyltransferase and in HDL rearrangements
J. Lipid Res.,
March 1, 2001;
42(3):
379 - 389.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. Holvoet, B. De Geest, S. Van Linthout, M. Lox, S. Danloy, K. Raes, and D. Collen
The Arg123-Tyr166 Central Domain of Human ApoAI Is Critical for Lecithin:Cholesterol Acyltransferase-Induced Hyperalphalipoproteinemia and HDL Remodeling in Transgenic Mice
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2000;
20(2):
459 - 466.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. McManus, B. R. Scott, V. Franklin, D. L. Sparks, and Y. L. Marcel
Proteolytic Degradation and Impaired Secretion of an Apolipoprotein A-I Mutant Associated with Dominantly Inherited Hypoalphalipoproteinemia
J. Biol. Chem.,
June 8, 2001;
276(24):
21292 - 21302.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|